Halozyme Therapeutics Inc (HALO) — Cash Flow Quality Index
Halozyme Therapeutics Inc (HALO) has a Cash Flow Quality Index of 1.02x as of September 2025. Operating cash flow of $178.60 Million exceeds net income of $175.22 Million, indicating high earnings quality where cash backs reported profits. Explore HALO operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Halozyme Therapeutics Inc Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Halozyme Therapeutics Inc across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Halozyme Therapeutics Inc cash conversion from operations.
Annual Cash Flow Quality Index for Halozyme Therapeutics Inc (2017–2024)
Year-by-year earnings quality comparison for Halozyme Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.08x | $479.06 Million | $444.09 Million | ▼ -21.8% |
| 2023 | 1.38x | $388.57 Million | $281.59 Million | ▲ +16.2% |
| 2022 | 1.19x | $240.11 Million | $202.13 Million | ▲ +59.8% |
| 2021 | 0.74x | $299.44 Million | $402.71 Million | ▲ +73.1% |
| 2020 | 0.43x | $55.45 Million | $129.09 Million | ▼ -79.8% |
| 2017 | 2.13x | $134.05 Million | $62.97 Million | — |